Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 76Carcinoma, Hepatocellular 47Ovarian Neoplasms 40Carcinoma, Non-Small-Cell Lung 26Neoplasms 22Fallopian Tube Neoplasms 17Lung Neoplasms 15Neoplasm Metastasis 13Breast Neoplasms 13Glioblastoma 12Endometrial Neoplasms 12Brain Neoplasms 12Colonic Neoplasms 11Triple Negative Breast Neoplasms 10Rectal Neoplasms 10Uterine Cervical Neoplasms 9Liver Neoplasms 9Stomach Neoplasms 8Colorectal Cancer Metastatic 7Pancreatic Neoplasms 6Advanced Solid Tumors 6Recurrence 5Melanoma 5Glioma 5Carcinoma, Renal Cell 5Carcinoma, Ovarian Epithelial 5Biliary Tract Neoplasms 5Solid Tumor 4Meningeal Carcinomatosis 4Gastrointestinal Neoplasms 4

Interventions

Leucovorin 2Fluorouracil 2Cetuximab 2Bevacizumab 2spartalizumab 1sintilimab 1Radiotherapy 1Radiation Dose Hypofractionation 1Oxaliplatin 1Irinotecan 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Locally Recurrent Rectal Cancer × Bevacizumab × Clear all
NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Fudan University

Phase 2 Recruiting
44 enrolled
Gastrointestinal

Locally Recurrent Rectal Cancer

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Fudan University

Phase 2 Recruiting
221 enrolled
Gastrointestinal

Locally Recurrent Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡